Drug Profile
Research programme: IE86 antagonists - Signal
Alternative Names: IE86 antagonists research programme - SignalLatest Information Update: 07 Nov 2003
Price :
$50
*
At a glance
- Originator Signal Research Division
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 07 Nov 2003 Discontinued - Preclinical for Cytomegalovirus infections treatment in USA (unspecified route)
- 27 Aug 2001 No-Development-Reported for Cytomegalovirus infections in USA (Unknown route)
- 07 Sep 2000 Signal Pharmaceuticals has been acquired by Celgene